TrialBlood2020

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.

Constantine S Tam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.